The Journal of international medical research
-
The pharmacokinetic and clinical properties of a modified release formulation of the alpha 2-adrenergic agonist tizanidine are reviewed. Therapy with conventional tizanidine tablets is effective in the relief of spasticity, but it has a short half-life, resulting in it having to be administered three or four times daily. The modified release capsules have retard characteristics which allow the drug to be given as a once-daily dosage. ⋯ Body weight, blood pressure, heart rate and haematological or biochemical measures were not adversely affected. The initial recommended dose of modified release tizanidine is one capsule per day of 6 mg, which may be increased gradually to 24 mg. A daily dose of 12 mg modified release tizanidine was used in 50% of patients studied.
-
Comparative Study Clinical Trial Controlled Clinical Trial
Etizolam in the treatment of generalized anxiety disorder: a controlled clinical trial.
A total of 45 patients with generalized anxiety disorder were treated twice daily for 2 weeks, on a double-blind basis, with 0.5 mg etizolam, 0.5 mg alprazolam or 3 mg bromazepam, and symptoms were assessed using Hamilton's rating scale for anxiety and Hamilton's rating scale for depression. Patients then received the same drug for a further 2 weeks, the drugs being given three times daily if a poor response was observed during the first 2 weeks. ⋯ Etizolam also possessed a more marked antidepressant effect than did alprazolam or bromazepam. There were no differences in the tolerability of the three drugs.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Analgesic efficacy and safety comparison of ketorolac tromethamine and Doleron for the alleviation of orthopaedic post-operative pain.
The analgesic efficacy and safety of ketorolac tromethamine (ketorolac), a potent analgesic with anti-inflammatory and antipyretic activities, were evaluated and compared with Doleron, a combination analgesic, in 115 patients with moderate to severe orthopaedic post-operative pain. This was a randomized, double-blind (double-dummy), parallel-group comparison of a single oral dose of one capsule of 10 mg ketorolac with a single oral dose of two Doleron tablets (each tablet contained 150 mg dextropropoxyphene napsylate, 350 mg aspirin and 150 mg phenazone). During the 6 h following treatment, 80% of ketorolac treated patients and 82% of Doleron treated patients experienced adequate pain relief. ⋯ Nausea (two patients in each treatment group), vertigo (none on ketorolac, three on Doleron) and sore throat (none on ketorolac, two on Doleron) were the only drug-related adverse events reported by more than one person in a treatment group during the trial. A total of 82% of patients given ketorolac and 76% given Doleron experienced no adverse events. A single oral dose of 10 mg ketorolac was shown to be as effective and safe as two Doleron tablets in the treatment of moderate to severe orthopaedic post-operative pain.
-
Randomized Controlled Trial Comparative Study Clinical Trial Controlled Clinical Trial
Comparative study of ketorolac and paracetamol/codeine in alleviating pain following gynaecological surgery.
In a randomized, double-blind, multiple-dose, parallel study of 107 patients, the safety and analgesic efficacy of single and multiple doses of orally administered ketorolac tromethamine (10-40 mg/day) were compared with orally administered paracetamol (1000-4000 mg/day)/codeine (60-240 mg/day) for treating moderate to severe pain after gynaecological surgery. Both drugs effectively reduced pain intensity. After the first dose of medication, over 90% of the patients in each treatment group reported pain reduction of at least 50%. ⋯ No statistically significant differences in analgesic efficacy were observed in the two treatment groups. Ketorolac tromethamine-treated patients reported a total of 62 adverse events (17 considered drug-related) and the paracetamol/codeine-treated patients reported 65 (20 considered drug-related); the adverse event profiles of the two treatment regimens were similar. Thus, both the single and the multiple doses of ketorolac tromethamine (10 mg) alleviated moderate to severe pain after gynaecological surgery as safely and efficaciously as paracetamol (1000 mg)/codeine (60 mg).
-
Randomized Controlled Trial Clinical Trial Controlled Clinical Trial
Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics.
A controlled, parallel group study of the analgesic efficacy of flupirtine maleate, was compared against diclofenac sodium in 40 orthopaedic patients with post-operative pain. Clinically, both drugs were of equal analgesic efficacy. A mathematical model has been developed, however, to evaluate the speed, intensity and duration of the analgesic effect and provides data which significantly favour flupirtine maleate in the treatment of these patients.